Olaparib

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Olaparib

Examples of brand names: Lynparza [EU/DE]

ATC code: L01XK01

Main use (for orientation): Selected cancers

Documented research summary

New CBD/olaparib cell combination from 2026 recorded; not a clinical pharmacokinetic or treatment recommendation.

Uncertainties and limitations

Single-ingredient oral product for human use in the US SPL; no claim regarding German brand availability or authorisation.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0184

Type of result: Preclinical evidence

Observation: The combination increased cytotoxicity, apoptosis and G2/M arrest, particularly in 3D models.

Mechanism: DNA-damage response/cell cycle

Study type: Cell / ex-vivo experiment

Context studied: BRCA-wild-type breast cancer cells MDA-MB-231/MCF-7 and HCC-70 spheroids.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: Abstract read, no patient pharmacokinetic data; no dosage or treatment recommendation.

Original sources for this finding: Cannabidiol potentiates olaparib-induced cytotoxicity through cell cycle arrest and DNA damage modulation in breast cancer cells. [BMED42048036]

References and access status

[V2_LABEL_D0392] LYNPARZA (OLAPARIB) TABLET, FILM COATED [ASTRAZENECA PHARMACEUTICALS LP]

Original source / bibliographic reference

Authors: AstraZeneca Pharmaceuticals LP

Year: 2025

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED42048036] Cannabidiol potentiates olaparib-induced cytotoxicity through cell cycle arrest and DNA damage modulation in breast cancer cells.

Original source / bibliographic reference

Authors: Deniz C, Yüksel B, Cebeci E, Şahin F.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.1007/s11010-026-05550-w

PMID: 42048036

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility